Relative risks of the composite end point for carriers versus noncarriers
| Allele . | Placebo . | Orbofiban treated . | P for interaction . |
|---|---|---|---|
| COL3A1-1 | 2.14 (1.04-4.39) | 0.73 (0.46-1.15) | .006 |
| COL3A1-2 | 1.45 (0.85-2.47) | 0.94 (0.61-1.47) | .29 |
| COL3A1-3 | 0.53 (0.28-0.98) | 1.65 (1.07-2.55) | .002 |
| COL3A1-4 | 0.56 (0.14-2.30) | 0.34 (0.11-1.07) | .56 |
| Allele . | Placebo . | Orbofiban treated . | P for interaction . |
|---|---|---|---|
| COL3A1-1 | 2.14 (1.04-4.39) | 0.73 (0.46-1.15) | .006 |
| COL3A1-2 | 1.45 (0.85-2.47) | 0.94 (0.61-1.47) | .29 |
| COL3A1-3 | 0.53 (0.28-0.98) | 1.65 (1.07-2.55) | .002 |
| COL3A1-4 | 0.56 (0.14-2.30) | 0.34 (0.11-1.07) | .56 |
Data are presented as relative risk (95% confidence interval) based on a Cox proportional hazards model that adjusted for age, sex, and country, comparing risk in carriers with that in noncarriers.